The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis

References

• Skrzypski M, Jassem J. Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treat Rev. 2018 May;66:114–121.
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr., Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452–1460.
   PubMedGoogle Scholar
• Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181–2190.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919–1929.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Riely GJ, Yu HA. EGFR: the Paradigm of an Oncogene-Driven Lung Cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2015 May 15;21(10):2221–2226.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009 May;10(5):432–433.
   PubMed Web of Science ®Google Scholar
• Iwama E, Nakanishi Y, Okamoto I. Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. Expert Rev Anticancer Ther. 2018 Mar;18(3):267–276.
   PubMed Web of Science ®Google Scholar
• Li F, Bai H, Li X, et al. [Role of EGFR mutation status in patients with stage III non-squamous non-small cell lung cancer treated with chemoradiotherapy]. Zhongguo Fei Ai Za Zhi. 2011 Sep;14(9):715–718.
   PubMedGoogle Scholar
• Soon YY, Vellayappan B, Tey JCS, et al. Impact of epidermal growth factor receptor sensitizing mutations on outcomes of patients with non-small cell lung cancer treated with definitive thoracic radiation therapy: a systematic review and meta-analysis. Oncotarget. 2017 Dec 12;8(65):109712–109722.
   PubMedGoogle Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. 2011.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. Bmj. 2003 Sep 6;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Park SE, Noh JM, Kim YJ, et al. EGFR mutation is associated with short progression free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy. Cancer Res Treat.  2019 Apr;51(2):493-501 .
   Google Scholar
• Akamatsu H, Kaira K, Murakami H, et al. The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy. Am J Clin Oncol. 2014 Apr;37(2):144–147.
   PubMed Web of Science ®Google Scholar
• Yagishita S, Horinouchi H, Katsui Taniyama T, et al. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):140–148.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Hida T, Oya Y, et al. EGFR mutation impact on definitive concurrent chemoradiation therapy for inoperable stage III adenocarcinoma. J Thorac Oncol. 2015 Dec;10(12):1720–1725.
   PubMed Web of Science ®Google Scholar
• Ishihara M, Igawa S, Sasaki J, et al. Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status. Oncol Lett. 2017 Jul;14(1):885–890.
   PubMed Web of Science ®Google Scholar
• Lim YJ, Chang JH, Kim HJ, et al. superior treatment response and in-field tumor control in epidermal growth factor receptor-mutant genotype of stage III nonsquamous non-small cell lung cancer undergoing definitive concurrent chemoradiotherapy. Clin Lung Cancer. 2017 May;18(3):e169–e178.
   PubMed Web of Science ®Google Scholar
• Ochiai S, Nomoto Y, Watanabe Y, et al. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non-small cell lung cancer: a literature review and pooled analysis. J Radiat Res. 2016 Sep;57(5):449–459.
   PubMed Web of Science ®Google Scholar
• Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by- two factorial phase 3 study. Lancet Oncol. 2015 Feb;16(2):187–199.
   PubMed Web of Science ®Google Scholar
• Roach MC, Bradley JD, Robinson CG. Optimizing radiation dose and fractionation for the definitive treatment of locally advanced non-small cell lung cancer. J Thorac Dis. 2018 Aug;10(Suppl 21):S2465–S2473.
   PubMedGoogle Scholar
• Lin Q, Liu YE, Ren XC, et al. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial. Radiat Oncol. 2013 Aug 17;8(1):201.
   PubMed Web of Science ®Google Scholar
• Jeter MD, Gomez D, Nguyen QN, et al. Simultaneous integrated boost for radiation dose escalation to the gross tumor volume with intensity modulated (photon) radiation therapy or intensity modulated proton therapy and concurrent chemotherapy for stage II to III Non-small cell lung cancer: a phase 1 study. Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):730–737.
   PubMed Web of Science ®Google Scholar
• Kong FM, Ten Haken RK, Schipper M, et al. Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: a phase 2 clinical trial. JAMA Oncol. 2017 Oct 1;3(10):1358–1365.
   PubMed Web of Science ®Google Scholar
• Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20;26(15):2450–2456.
   PubMed Web of Science ®Google Scholar
• Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: aretrospective multi-institutional analysis. J Clin Oncol. 2017 Apr 1;35(10):1070–1077.
   PubMed Web of Science ®Google Scholar
• Shin DY, Na II, Kim CH, et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J Thorac Oncol. 2014 Feb;9(2):195–199.
   PubMed Web of Science ®Google Scholar
• Wu YL, Herbst RS, Mann H, et al. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in egfr mutation-positive early-stage nsclc after complete surgical resection. Clin Lung Cancer. 2018 Jul;19(4):e533–e536.
   PubMed Web of Science ®Google Scholar